KRAS and cancer: Given that the number of human malignancies in which DUBs show changes in their expression levels or are mutated has substantially grown over the last few years, Fraile and colleagues, using KRAS-dependent cancer cells as a model, performed an shRNA-based synthetic lethal screen using a custom library of shRNAs targeting most DUBs.